Literature DB >> 901977

RBE of neutrons generated by 50 MeV deuterons on beryllium for control of artificial pulmonary metastases of a mouse fibrosarcoma.

K A Mason, H R Withers.   

Abstract

Artificial pulmonary metastases of a mouse fibrosarcoma were produced by the intravenous injection of 10(4) cells admixed with 2 X 10(6) plastic microspheres into mice preconditioned with 600 rad whole-body irradiation 24 hours earlier. Four days after injection of tumour cells, mice were irradiated with neutrons generated by 50 MeV deuterons on Be at the Texas A & M Variable Energy Cyclotron or with 137Cs gamma rays. One, three or six fractions of radiation were delivered on a three-hour fractionation schedule. Surviving lung metastases were scored macroscopically 16 days after irradiation. The data indicate that: (1) the RBE (n/gamma) was in the range 1.6-2.6 depending on the size of dose per fraction; (2) the slopes of the gamma-ray curves decreased with increasing fraction number (i.e. decreasing fraction size); (3) the slopes of the neutron curves decreased only slightly with increasing fraction number (and decreasing fraction size); (4) no additional sparing was achieved by further fractionating doses of neutrons of 300 rad or less.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 901977     DOI: 10.1259/0007-1285-50-597-652

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  3 in total

1.  Enhancement of lung colony formation by admixing irradiated with viable tumor cells: dependence on host status.

Authors:  L Milas; M Iwakawa; N Hunter
Journal:  Clin Exp Metastasis       Date:  1987-09       Impact factor: 5.150

2.  Increase in radiosensitivity of lung micrometastases by hyperbaric oxygen.

Authors:  L Milas; N M Hunter; H Ito; W A Brock; L J Peters
Journal:  Clin Exp Metastasis       Date:  1985 Jan-Mar       Impact factor: 5.150

3.  Combination of interleukin-2 and irradiation in therapy of murine tumors.

Authors:  N Hunter; T Nakayama; H Ito; S Woo; L Milas
Journal:  Clin Exp Metastasis       Date:  1992-11       Impact factor: 5.150

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.